financetom
Business
financetom
/
Business
/
ECB opposes favourable capital treatment for BNP Paribas' AXA deal, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ECB opposes favourable capital treatment for BNP Paribas' AXA deal, source says
Apr 11, 2025 9:08 AM

PARIS, April 11 (Reuters) - The European Central Bank is

opposed to BNP Paribas using a favourable capital

treatment for its deal to buy French insurer AXA's

asset management business, a person with knowledge of the matter

said.

The ECB's view could have negative implications for

consolidation across Europe's financial industry, making certain

deals more expensive.

BNP shares fell on Friday and were last down 3%,

underperforming the wider European banking sector, which dropped

about 0.2%.

BNP Paribas and AXA declined to comment. The ECB did not

immediately respond to a request for comment.

The French bank had asked the ECB to use what is known as

the "Danish Compromise" that provides favourable capital

treatment in asset management takeovers carried out through

banks' insurance businesses.

This makes an asset management acquisition cheaper for the

buyer in terms of the hit to its regulatory capital.

The compromise lets banks risk-weight their insurance

investments instead of deducting them in full from their

capital.

BNP Paribas's AXA deal was agreed last year but is yet to be

finalised.

The ECB has said previously it would decide on the use of

the Danish Compromise on a case-by-case basis.

Last month, the ECB took a negative stance on Italian bank

Banco BPM benefiting from the same rule for its

acquisition of a local asset manager.

Banking executives are keen to see what stance the ECB

takes, with industry sources saying a positive opinion on the

use of the Danish Compromise would support further dealmaking.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roblox Insider Sold Shares Worth $300,000, According to a Recent SEC Filing
Roblox Insider Sold Shares Worth $300,000, According to a Recent SEC Filing
Dec 13, 2024
05:52 PM EST, 12/13/2024 (MT Newswires) -- Mark Reinstra, Chief Legal Officer & Corporate Secretary, on December 11, 2024, sold 5,000 shares in Roblox ( RBLX ) for $300,000. Following the Form 4 filing with the SEC, Reinstra has control over a total of 504,315 shares of the company, with 278,161 shares held directly and 226,154 controlled indirectly. SEC Filing:...
Roblox Insider Sold Shares Worth $2,693,805, According to a Recent SEC Filing
Roblox Insider Sold Shares Worth $2,693,805, According to a Recent SEC Filing
Dec 13, 2024
05:51 PM EST, 12/13/2024 (MT Newswires) -- Manuel Bronstein, Chief Product Officer, on December 11, 2024, sold 44,888 shares in Roblox ( RBLX ) for $2,693,805. Following the Form 4 filing with the SEC, Bronstein has control over a total of 573,266 shares of the company, with 573,266 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1315098/000131509824000309/xslF345X05/wk-form4_1734130068.xml ...
US EPA says it has not made decision on California 2035 vehicle waiver
US EPA says it has not made decision on California 2035 vehicle waiver
Dec 13, 2024
WASHINGTON (Reuters) - The U.S. Environmental Protection Agency said on Friday it has not made a decision yet on whether to approve California's landmark plan to end the sale of gasoline-only vehicles by 2035. A senior California Air Resources Board official told Reuters in October the state expects the EPA to grant a waiver under the Clean Air Act to...
US FDA approves Checkpoint's skin cancer drug
US FDA approves Checkpoint's skin cancer drug
Dec 13, 2024
Dec 13 (Reuters) - The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' ( CKPT ) drug for treatment of two types of skin cancer. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved